GB1520200A - Antitumour vaccines and their preparation - Google Patents

Antitumour vaccines and their preparation

Info

Publication number
GB1520200A
GB1520200A GB53723/76A GB5372376A GB1520200A GB 1520200 A GB1520200 A GB 1520200A GB 53723/76 A GB53723/76 A GB 53723/76A GB 5372376 A GB5372376 A GB 5372376A GB 1520200 A GB1520200 A GB 1520200A
Authority
GB
United Kingdom
Prior art keywords
species
virus
mammal
oncolysate
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB53723/76A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The Wistar Institute
Original Assignee
The Wistar Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wistar Institute filed Critical The Wistar Institute
Publication of GB1520200A publication Critical patent/GB1520200A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB53723/76A 1976-06-01 1976-12-23 Antitumour vaccines and their preparation Expired GB1520200A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/691,486 US4108983A (en) 1976-06-01 1976-06-01 Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors

Publications (1)

Publication Number Publication Date
GB1520200A true GB1520200A (en) 1978-08-02

Family

ID=24776726

Family Applications (1)

Application Number Title Priority Date Filing Date
GB53723/76A Expired GB1520200A (en) 1976-06-01 1976-12-23 Antitumour vaccines and their preparation

Country Status (8)

Country Link
US (1) US4108983A (cg-RX-API-DMAC7.html)
JP (1) JPS52148617A (cg-RX-API-DMAC7.html)
AU (1) AU511071B2 (cg-RX-API-DMAC7.html)
CA (1) CA1073814A (cg-RX-API-DMAC7.html)
DE (1) DE2705610A1 (cg-RX-API-DMAC7.html)
FR (1) FR2353641A1 (cg-RX-API-DMAC7.html)
GB (1) GB1520200A (cg-RX-API-DMAC7.html)
NZ (1) NZ182891A (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0037441B1 (en) * 1980-03-10 1984-05-09 Seiji Arakawa Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein
JPS5835121A (ja) * 1981-08-20 1983-03-01 ビラス・ヴィー・リクハイト 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用
US4652522A (en) * 1983-07-05 1987-03-24 The University Of Pennsylvania Continuous lymphocyte cell lines, their production and use
JPS6038328A (ja) * 1983-08-11 1985-02-27 Handai Biseibutsubiyou Kenkyukai 抗腫瘍免疫誘導の増強法
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
US6338853B1 (en) 1987-04-23 2002-01-15 Jean-Claude Bystryn Anti-cancer vaccine
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
WO1990011765A1 (en) * 1989-04-11 1990-10-18 Board Of Regents, The University Of Texas System Antitumor preparation obtained following oncolysate treatment
US5290551A (en) * 1990-05-08 1994-03-01 Thomas Jefferson University Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten
US7585512B1 (en) 1990-05-08 2009-09-08 Thomas Jefferson University Composition and method of using tumor cells
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
US6586411B1 (en) 2000-08-16 2003-07-01 Mayo Foundation For Medical Education And Research System for monitoring the location of transgenes
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US7015205B1 (en) 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7118740B1 (en) * 2000-09-22 2006-10-10 Mayo Foundation For Medical Education And Research Method for limiting the growth of cancer cells using an attenuated measles virus
DK1984007T3 (en) * 2006-02-13 2015-12-07 Oncolytics Biotech Inc Application of Low-dose local immunosuppression for amplification of viral oncolytic therapy
US9951117B2 (en) 2010-09-02 2018-04-24 Mayo Foundation For Medical Education And Research Vesicular stomatitis viruses
JP5944901B2 (ja) 2010-09-02 2016-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 水疱性口内炎ウイルス
US9623096B2 (en) 2011-11-09 2017-04-18 Celverum Inc. Virally infected hematopoietic cells and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3553312A (en) * 1968-02-26 1971-01-05 Flow Lab Process for producing rubella-virus hemagglutinating antigen

Also Published As

Publication number Publication date
NZ182891A (en) 1984-03-30
FR2353641B1 (cg-RX-API-DMAC7.html) 1980-07-18
AU2173577A (en) 1978-08-03
CA1073814A (en) 1980-03-18
DE2705610A1 (de) 1977-12-15
AU511071B2 (en) 1980-07-24
FR2353641A1 (fr) 1977-12-30
DE2705610C2 (cg-RX-API-DMAC7.html) 1989-08-03
US4108983A (en) 1978-08-22
JPS52148617A (en) 1977-12-10

Similar Documents

Publication Publication Date Title
Heppner Studies on serum‐mediated inhibition of cellular immunity to spontaneous mouse mammary tumors
NO912642D0 (no) Fremstilling av proteiner ved bruk av homolog rekombinasjon.
EA199800272A1 (ru) Фактор, стимулирующий дендритные клетки
AU588885B2 (en) Production of viral antigens
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
US3674864A (en) Process for stabilizing preparations of interfering viruses
Brunner et al. Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells.
GB1177635A (en) Cell Stains.
Müllbacher et al. An improved colorimetric assay for T cell cytotoxicity in vitro
Calnek Lymphomagenesis in Marek's disease
IE40221L (en) Influenza vaccines
Price et al. Induction of immunity to chemically-induced rat tumours by cellular or soluble antigens
Damjanov et al. Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host
SHIMOJO et al. The nature of tumor antigen of adenovirus type 12 and its formation in cultured cells after infection
US3418210A (en) Hamster ascites tumor cell line bhk 21/c.13/t.6/ascites useful in submerged serum-free agar cultures to support virus growth
CN106978397A (zh) 一种人dc-cik免疫活性细胞及其制备方法
ATE86308T1 (de) Menschlicher b-lymphotroper virus (hblv), isolierung und erzeugnisse.
GB1358321A (en) Method od tissue cell culture
Clark et al. Sv40‐induced transformation of cells of the lizard Gekko gecko
GB1481650A (en) Chemical processes and products
ES2012815A6 (es) Un metodo para producir peptidos antigenicos relacionados con el antigeno p97 asociado a melanoma, y para preparar vacunas que los contienen.
SU769811A1 (ru) Вакцинный штамм вируса гриппа А (Уфа) 771/1е ( @ )
Abramoff et al. Cytotoxicity of heterologous immune chicken serum to normal and neoplastic mouse tissues in culture
Traul et al. Antigenic comparison of Rauscher murine leukemia virus cultivated in human embryo and mouse cells
Abid et al. Antitumour activity of adenovirus-12 structural proteins against Moloney sarcoma tumours in mice

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee